An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Active autoimmune cytopenia
Relapsed/refractory after ≥1 prior treatment
Body weight ≥ 55 kg
Willing to comply with and study requirements and procedures
Previous treatment with a BCMA-targeted therapy
Clinically significant infection within 3 months of screening
Major surgery or splenectomy within 3 months of screening or planned during the study
Pregnant or breastfeeding
Sequential
OM336
DrugOM336 is an engineered bispecific antibody directed against BCMA and CD3
Safety and Tolerability
Incidence and severity of treatment emergent adverse events (TEAEs)
Safety and Tolerability
Incidence and severity of treatment-emergent adverse events (TEAEs)
To assess the pharmacokinetics (PK) of OM336
Serum concentrations of OM336
Detection of anti-drug antibodies
Detection of anti-drug antibodies
Click on the lead sponsor to view all of their trials.
